ArticleIndian journal of endocrinology and metabolism
Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Activation of G protein-coupled receptors by ketone bodies: Clinical implication of the ketogenic diet in metabolic disorders.Frontiers in endocrinology · 2022Review
- Prevalence of Bacterial Urinary Tract Infection Among Patients With Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study.Journal of the ASEAN Federation of Endocrine Societies · 2022Article
- Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.Endocrine · 2017Article
- Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2017Review
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Nature reviews. Endocrinology · 2016Review
- Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.Canadian family physician Medecin de famille canadien · 2016Article
- [L'acidocétose euglycémique dans le diabète de type 2 traité avec un inhibiteur du cotransporteur sodium-glucose de type 2].Canadian family physician Medecin de famille canadien · 2016Article
- A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Indian journal of endocrinology and metabolismReview
- Sodium glucose transporter 2 inhibition, euglycemic ketosis and bone mineral loss: Refining clinical practices.Indian journal of endocrinology and metabolismArticle
- Ketoacidosis in diabetic subjects treated with inhibitors of Na(+)-glucose co-transporters type-2: New mechanisms?Indian journal of endocrinology and metabolismArticle
- Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy.Journal of postgraduate medicineReview
- Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect.Indian journal of endocrinology and metabolismArticle
- Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight.Indian journal of endocrinology and metabolismReview
- Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium glucose transporter 2 (SGLT2) inhibitors are a recently developed class of drug that have been approved for use in type 2 diabetes. Their unique extra-pancreatic glucuretic mode of action has encouraged their usage in type 1 diabetes as well. At the same time, reports of pseudo ketoacidosis and ketoacidosis related to their use have been published. No clear mechanism for this phenomenon has been demonstrated so far. This communication delves into the biochemical effects of SGLT2 inhibition, discusses the utility of these drugs and proposes steps to maximize safe usage of the molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.